Back to search results

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Folliculotropic Mycosis Fungoides · Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma · Recurrent Mycosis Fungoides · Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma · Refractory Mycosis Fungoides · Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified · Sezary Syndrome · Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • City of Hope Medical Center, Duarte, California, United States

    Contact: Study coordinator (Christiane Querfeld, MD) · cquerfeld@coh.org · 626-256-4673
    Contact: Principal Investigator (Christiane Querfeld, MD)

  • Memorial Sloan-Kettering Cancer Center, New York, New York, United States

    Contact: Study coordinator (Steven M. Horwitz, MD) · horwitzs@mskcc.org · 212-639-3045
    Contact: Principal Investigator (Steven M. Horwitz, MD)

  • Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Pierluigi Porcu, MD) · Pierluigi.Porcu@jefferson.edu · 215-955-8874
    Contact: Principal Investigator (Pierluigi Porcu, MD)

  • M D Anderson Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (Michelle A. Fanale, MD) · mfanale@mdanderson.org · 713-792-2860
    Contact: Principal Investigator (Michelle A. Fanale, MD)
Study leads

  • Christiane Querfeld, MD

    Principal Investigator

    City of Hope Medical Center

View source on ClinicalTrials.gov(opens in a new tab)